The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Frank Russell Company
Advised LSEG on the proposed acquisition of Frank Russell Company, the number one provider of benchmarks to US-focused equity funds and a leading provider of multi-asset class investment solutions, from Northwestern Mutual Life Insurance Company, including acting as Joint Sponsor to LSEG on its $1.6 billion rights issue
Clinuvel Pharmaceuticals Limited
Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases
Global Trade Information Services, Inc.
Advised Global Trade Information Services, the world’s leading supplier of international merchandise trade data, on the sale of the company to IHS.
Cars.com
Advised Gannett Co., Inc. a media and marketing solutions company, on its acquisition of Cars.com (part of Classified Ventures, LLC), a provider of online auto advertising solutions and consumer content.
Siemens Health Services
Advised Cerner Corporation, a leader in healthcare information services, on the acquisition of the assets of Siemens Aktiengesellschaft’s healthcare information technology business unit, Siemens Health Services, for $1.3 billion in cash.
MannKind Corporation
Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.
Voya Financial, Inc.
Advised the Independent Committee of the Board of Directors of Voya Financial, Inc. in connection with Voya Financial, Inc.’s repurchase of 7.7mm shares (aggregate repurchase of $300mm) from ING Groep N.V.
Hitachi Appliances, Inc.
Advised Hitachi, LTD / Hitachi Appliances, Inc, a leading global industrial conglomerate focused on information and telecommunications systems, power systems and social systems, on their formation of a global HVAC joint venture with Johnson Controls
Wireline assets of Verizon Communications in California, Florida and Texas
Advised the Board of Directors of Frontier in connection with its acquisition of wireline assets from Verizon in California, Florida and Texas
GFI Group Inc.
Advised the Special Committee of GFI Group Inc. on its sale to BGC Partners, Inc.
Softcard (JVL Ventures, LLC)
Advised Softcard, a joint venture of AT&T, Verizon and T-Mobile focused on mobile payments and commerce, on the sale of certain assets to Google
Nordstrom, Inc. (Credit Card Assets)
Advised The Toronto-Dominion Bank Group on its acquisition of Nordstrom, Inc.’s credit card assets
Telecity Group plc
Advised Telecity Group plc, Europe’s leading provider of premium carrier-neutral data centres, on a recommended cash and share offer from Equinix, Inc. a leading US provider of colocation data centre services globally
Portfolio of GlaxoSmithKline plc consumer and OTC brands
Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc
Aralez Pharmaceuticals Inc.
Advised QLT Inc. on its strategic equity investment in Aralez Pharmaceuticals Inc., a newly formed global specialty pharmaceutical company resulting from the business combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc., and the special distribution of the Aralez shares to QLT shareholders.
Altegra Health, Inc.
Advised Emdeon, a leading healthcare information technology company, on the acquisition of Altegra Health, a national provider of technology and intervention platforms for value-based healthcare
Allergan Generics
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
International Medical Group, Inc.
Advised International Medical Group, Inc., a leader in the global insurance and assistance services market, on its sale to ABRY Partners
DCG Systems, Inc.
Advised FEI Company, a designer and manufacturer of a broad range of high-performance microscopy workflow solutions, on its $160 million acquisition of DCG Systems, Inc., a leading supplier of electrical fault characterization, localization and editing equipment
Aesynt, Inc.
Advised Omnicell, Inc., a leading supplier to health systems of automation solutions and business analytics software for medication and supply management, on the acquisition of Aesynt, Inc., a provider of integrated pharmacy automation solutions for hospitals and health systems
Heartland Payment Systems, Inc.
Advised Heartland Payment Systems, Inc., one of the nation’s largest payment companies, on its sale to Global Payments Inc., a leading worldwide provider of payment technology services
Airopack Technology Group AG
Advised Airopack Technology Group, developer of a revolutionary all-plastic dispenser, on a €120 million debt and equity investment from funds managed by affiliates of Apollo Global Management, and the concurrently announced proposed acquisition of the 50% stake it does not already own in Airolux AG, its joint venture with Resilux NV
Perseus Books LLC
Advised Perseus Books LLC, a leading independent publishing company, on the sale of its publishing business to Hachette Book Group, Inc.
Perseus Books LLC
Advised Perseus Books LLC, a leading independent publishing company, on the sale of its client services business to Ingram Content Group Inc.
Boehringer Ingelheim
Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.